Pharmaceutical - Pharmaceutical, Pricing

Filter

Current filters:

PharmaceuticalPricing

Popular Filters

1 to 25 of 598 results

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

New report: The myth of high Danish medicine prices

20-10-2014

The price-cap agreements between Lif, the Danish pharmaceutical industry group, and the government help…

DenmarkGenericsPharmaceuticalPricing

NICE reverses guidance on Novartis’ Glivec for GIST

NICE reverses guidance on Novartis’ Glivec for GIST

17-10-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Call for India’s Prime Minister to restore drug price caps

14-10-2014

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, with its affiliate country program,…

IndiaPatentsPharmaceuticalPoliticsPricing

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

IQWiG finds added benefit of Novartis’ Gilenya not proven

IQWiG finds added benefit of Novartis’ Gilenya not proven

10-10-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

GermanyGilenyaNeurologicalNovartisPharmaceuticalPricingRegulation

Cancer care is advancing, but costs cannot be ignored, says UnitedHealthcare SVP

Cancer care is advancing, but costs cannot be ignored, says UnitedHealthcare SVP

09-10-2014

Cancer care is advancing, but policymakers and the cancer care community must find ways to make it more…

HealthcareOncologyPharmaceuticalPricingUSA

Report: Israel's pharma market set to reach $2.3 billion by 2020

Report: Israel's pharma market set to reach $2.3 billion by 2020

08-10-2014

Technological advances in the medical field, high expenditure on R&D and a robust economy provide the…

IsraelMarkets & MarketingPharmaceuticalPricingResearch

Data uncertainties mean NICE does not recommend Roche leukemia drug

Data uncertainties mean NICE does not recommend Roche leukemia drug

03-10-2014

In yet another rejection of the company’s cancer drugs, the UK drugs watchdog, the National Institute…

GazyvaroOncologyPharmaceuticalPricingRegulationRocheUK

NICE recommends Lundbeck’s Selincro for alcohol dependence

NICE recommends Lundbeck’s Selincro for alcohol dependence

02-10-2014

Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) recommends…

Biotie TherapiesLundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Bayer’s Jadelle to be listed in New Zealand

Bayer’s Jadelle to be listed in New Zealand

26-09-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

BayerJadelleMarkets & MarketingNew ZealandPharmaceuticalPricingReproductiveWomen's Health

Top 100 US drug pricing average jumps seven-fold to $9,400 in 2014

Top 100 US drug pricing average jumps seven-fold to $9,400 in 2014

26-09-2014

The median price of the top 100 drugs has skyrocketed from $1,260 in 2010 to $9,400 in 2014, representing…

PharmaceuticalPharmacologyPricingUnited StatesUSA

NICE opens consultation on three drugs for chronic bowel condition

NICE opens consultation on three drugs for chronic bowel condition

24-09-2014

Three drugs to treat ulcerative colitis, a chronic bowel condition, have not been proven to be more cost…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalPricingRegulationRemicadeSimponi InjectionUK

Greek pharma trade group SFEE warns on pharma budgets

Greek pharma trade group SFEE warns on pharma budgets

22-09-2014

The members of Greece’s pharma trade group SFEE have called on the government to urgently reset the…

FinancialGreeceLegalPharmaceuticalPricing

UK NICE consults on draft guidance for hepatitis C drug Olysio

UK NICE consults on draft guidance for hepatitis C drug Olysio

18-09-2014

In draft guidance published today UK drugs watchdog the National Institute for Health and Care Excellence…

Anti-viralsJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulationUK

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

15-09-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

Anti-viralsGermanyJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulation

Curious resilience of the $50,000-per-QALY threshold

28-08-2014

For more than two decades, the ratio of $50,000 per quality-adjusted life-year (QALY) gained by using…

HealthcarePharmaceuticalPricingRegulationUSA

USIBC concludes successful pharmaceutical mission to India

USIBC concludes successful pharmaceutical mission to India

28-08-2014

The US-India Business Council (USIBC) has concluded its Pharmaceutical Executive Mission to Delhi, India.…

IndiaPatentsPharmaceuticalPricingUSA

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

Grattan Institute admission shows Australia’s PBS savings proposal was wrong

Grattan Institute admission shows Australia’s PBS savings proposal was wrong

21-08-2014

The Grattan Institute’s proposal on Australia Pharmaceutical Benefits Scheme (PBS) savings has been…

AustraliaFinancialPharmaceuticalPricing

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

20-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products,…

Federal Joint CommitteeGermanyJakaviMyelofibrosisNovartisOncologyPharmaceuticalPricingRare diseasesRegulation

1 to 25 of 598 results

Back to top